Home・Akcijų sąrašas・BioNTech SE ADR

BioNTech SE ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

90.78 -1.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

88.01

Max

93.55

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-239M -541M
Pardavimai	-779M 120M
Pelnas, tenkantis vienai akcijai	-1.95
Pelno marža	-450.381
Darbuotojai	7,807
EBITDA	-383M -450M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+36.04% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.8B 23B
Ankstesnė atidarymo kaina	91.92
Ankstesnė uždarymo kaina	90.78

BioNTech SE ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-04 20:03; UTC

News

Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

2026-08-03 21:01; UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

2026-07-31 19:16; UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

2026-07-30 21:01; UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

2026-07-29 19:55; UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

2026-07-28 19:16; UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

2026-07-27 19:06; UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

2026-07-24 19:06; UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

2026-07-22 18:06; UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

2026-07-21 14:41; UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

2026-07-20 19:06; UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Akcijų palyginimas

Kainos pokytis

BioNTech SE ADR Prognozė

Kainos tikslas

By TipRanks

36.04% į viršų

12 mėnesių prognozė

Vidutinis 125.5 USD 36.04%

Aukščiausias 158 USD

Žemiausias 94 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioNTech SE ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių BioNTech SE ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac